Bloody or Well Done. How Would You Like Your Liver Biopsy, Sir?
NCT06231082 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78
Last updated 2024-05-07
Summary
This is a randomized comparative trial between percutaneous liver biopsy and EUS FNB guided liver biopsy in patients with parenchymal liver disease.
Studies so far have been shown that EUS FNB guided liver biopsy is non inferior to percutaneous liver biopsy in terms of efficacy, provided several conditions are met (type of needle, wet suction, actuations).
În terms of safety, it may be that EUS FNB have an advantage, as needle diameter is slightly smaller, needle is inserted under better visualisation especially in patients with large subcutaneous fat tissue and the possibility of examining the needle tract and plugging it with needle content if needed ("the blood patch technique").
However, although severe, the incidence of liver bleeding is low, so a comparative trial with the hypothesis that EUS FNB has fewer liver bleedings than percutaneous techniques would have a very large sample size.
A recent study found out that abdominal pain at 2 hours after procedure is predictive for liver bleeding.
So we have design a randomized prospective trial assuming that EUS FNB guided liver biopsy has significantly less abdominal pain at 2 hours after procedure when compared to percutaneous route, using abdominal pain at 2 hours as a surrogate marker for risk of liver bleeding.
Conditions
- Liver Disease Parenchymal
Interventions
- PROCEDURE
-
Group one - percutaneous (P)
Percutaneous procedure will be performed under standard conditions, under transabdominal ultrasound guidance. After choosing the optimum needle trajectory, the skin site will be marked, standard skin sterilization with iodine and surgical draping of the site will be performed. Local anesthesia of the site with gradual lidocaine solution infiltration of the skin and underlying planes will be performed. Under ultrasound guidance, with collaboration of the patient for the respiratory movements, one or two passages with a 16G needle will be performed (BARD Max Core 16G, Becton Dickinson, USA). Specimens will be collected in formalin and send to pathology for processing.
- PROCEDURE
-
Group two - EUS FNB (E)
EUS guided liver FNB will be performed under deep sedation with propofol under anesthesiology monitoring. A 19G gauge Franseen needle (Acquire 19G, Boston Scientific, USA) will be used with the "wet suction" technique. Before inserting into the operating channel, the stylet will be removed, and the needle will be primed with heparin (500UI/5ml). After liver puncture, the 20ml aspiration syringe will be attached. Three needle actuations will be performed, one or two passes in the left liver lobe. At the end of the 3rd actuation, the syringe aspiration will be stopped, the needle will be left in place in the liver parenchyma for 2 to 3 minutes. The liver needle path will be examined with Doppler ultrasound to look for possible bleeding. If present, about 25% of the needle content will be pushed in the liver path, as previously described - the "blood patch" technique.
Sponsors & Collaborators
-
Carol Davila University of Medicine and Pharmacy
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-06
- Primary Completion
- 2024-12-31
- Completion
- 2024-12-31
Countries
- Romania
Study Locations
More Related Trials
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
NCT07269301 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction
NCT05478603 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation
NCT01073202 ·Status: COMPLETED ·Phase: NA
-
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid
NCT01389973 ·Status: COMPLETED ·Phase: PHASE2
-
Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD
NCT02244944 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
NCT06719128 ·Status: COMPLETED ·Phase: PHASE1
-
The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation
NCT05732181 ·Status: COMPLETED ·Phase: NA
-
Endoscopic Ultrasound Shear Wave for Liver Fibrosis in MASLD Patients: The RUMIPAMBA Trial
NCT06102980 ·Status: RECRUITING ·Phase: NA
-
Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)
NCT04229901 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
NCT05882032 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
NCT03248882 ·Status: COMPLETED ·Phase: PHASE2
-
Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
NCT02021110 ·Status: COMPLETED ·Phase: PHASE2
-
Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment
NCT03309202 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis
NCT01452308 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Liver Regeneration Therapy Using Cultured Autologous BMSCs
NCT02327832 ·Status: UNKNOWN ·Phase: PHASE1
-
Efficacy and Safety of Hemoperfusion or Plasma Exchange Compared to Standard Medical Therapy in Patients With Acute on Chronic Liver Failure
NCT04013113 ·Status: UNKNOWN ·Phase: NA
-
Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects
NCT00812305 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of PK and Biomarkers After UDCA Administrations to Subjects Who Are Overweight and Have Liver Problems
NCT03000218 ·Status: UNKNOWN ·Phase: PHASE1
-
The EVARREST® Fibrin Sealant Patch Liver Study
NCT01993888 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study of Lyophilized Plasma in Patients With Liver Disease
NCT01547078 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
NCT02316717 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH
NCT03332940 ·Status: TERMINATED ·Phase: PHASE1
-
Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
NCT02026401 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Liver Health in Psoriatic Arthritis Patients Using Anti-TNF or Anti-IL17 Treatments
NCT06918886 ·Status: NOT_YET_RECRUITING
-
Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response
NCT07102979 ·Status: ENROLLING_BY_INVITATION ·Phase: NA